posted
eFoodSafety.com Inc. Subsidiary Knock-Out Technologies Ltd. Files for Patent Protection on Bird Flu Formulas; Citroxin and Citroxin O2 Secure 'Patent Pending' Status for Formulations E-mail or Print this story
19 April 2006, 09:45am ET
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--April 19, 2006--Patricia Gruden, president/CEO of eFoodSafety.com Inc. (OTCBB:EFSF), announced today that the company's wholly owned subsidiary, Knock-Out Technologies Ltd., has filed with the United States Patent and Trademark Office for patent protection on their bird flu formulations, Citroxin and Citroxin O2.
The board of directors determined that it was in the best interest of the shareholders to file for patent protection on Citroxin and Citroxin O2 at this time, rather than keep them as proprietary formulations.
The timing of the filing was especially important since the presence of the bird flu virus appears to be imminent in the United States.
The board of directors felt the safest way to protect the company's formulations was through patent protection, thus also giving the company more latitude and security when discussing the products and their components with interested third parties.
"This was a necessary systematic step that needed to be completed prior to commercialization of the product," stated Gruden.
About eFoodSafety.com Inc.
Mentioned Last Change EFSF 0.361 0.029dollars or (8.73%) eFoodSafety.com Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus -- EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus and Streptococcus, Avian Influenza and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars ( www.talsyn.com ). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism ( www.cinnergen.com ), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to be announced in the near future.
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Posts: 50 | Registered: Mar 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
